Hemispherx (HEB) Updates on FDA Panel Vote for Ampligen; Fails to Win Backing
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 7/15/2026
- Wall St edges higher with earnings in focus; chip stocks retreat
- U.S. headline producer inflation posts first one-month decrease since August 2025
- PayPal rallies 20% on report Stripe, Advent made $53 billion bid
- Oil prices sink, shrugging off renewed Middle East fighting
- ASML capacity upgrade soothes AI chip bottleneck fears
Hemispherx Biopharma (HEB) Investors Go For Ride Following FDA Panel Vote
December 20, 2012 5:34 PM ESTHemispherx Biopharma, Inc. (NYSE: HEB) saw heavy action on Thursday after news broke that its Ampligen drug was not proven effective in treatment for chronic fatigue. An FDA panel voted 9-4 against the efficacy of the drug. Several members cited need for additional... More
Hemispherx (HEB) fails to win FDA panel backing for Ampligen efficacy
December 20, 2012 4:29 PM ESTHemispherx Biopharma, Inc. (NYSE: HEB) fails to win FDA panel backing for Ampligen efficacy.... More
